Continuous Glucose Monitor Data
Buy and sell continuous glucose monitor data data. 24/7 blood sugar readings — CGM data trains diabetes management AI and even predicts meals and exercise effects.
No listings currently in the marketplace for Continuous Glucose Monitor Data.
Find Me This Data →Overview
What Is Continuous Glucose Monitor Data?
Continuous glucose monitors (CGM) are wearable biosensors that automatically measure blood glucose at regular intervals—ranging from every 1 to every 15 minutes—from interstitial fluid. These minimally invasive devices use a small sterile filament placed under the skin and transmit real-time glucose readings to mobile displays, smartwatches, or cycling computers. CGM data is transforming diabetes management and increasingly used by people without diabetes to optimize health and wellness, with FDA-cleared over-the-counter options now available. The technology enables event tagging (meals, exercise, medications) and generates continuous data streams that allow users to identify glycemic variability, detect hypoglycemia risks, and make timely corrective actions.
Market Data
USD 8.98 billion
Global CGM Market Size 2025
Source: IntechOpen
USD 17.12 billion
Projected Global Market 2030
Source: IntechOpen
13.76%
Global CGM CAGR (2025–2030)
Source: IntechOpen
USD 3.09 billion
Europe CGM Market 2025
Source: Market Data Forecast
USD 10.97 billion
Europe Projected Market 2034
Source: Market Data Forecast
Who Uses This Data
What AI models do with it.do with it.
Diabetes Management AI & Insulin Titration
Healthcare providers and AI systems use CGM data to titrate insulin doses, keep blood sugar levels stable, and help patients achieve target glycemic outcomes (A1C) while reducing severe hypoglycemia risk.
Sports Nutrition & Athletic Performance
Athletes and sports scientists use CGM data to optimize carbohydrate feeding timing and dosing, monitor glucose levels during exercise, and correlate glucose patterns with performance metrics and fatigue.
Wellness & Preventive Health Optimization
Non-diabetic individuals use CGM data to understand how dietary choices, meals, and exercise affect blood glucose levels, enabling personalized health and wellness optimization.
Clinical Research & Device Development
Medical device manufacturers and researchers analyze CGM datasets to validate sensor accuracy, develop advanced visualizations, calculate glycemic variability metrics, and support clinical trials.
Pricing depends on the proposed terms
We do not have a verified, comparable price for your dataset. Consider the permitted uses, license term, exclusivity, provenance, coverage and quality. A seller asking price is a proposal, not an appraisal or guaranteed sale. Compare prices only when the source, date, currency, unit and license scope are known.
What Buyers Expect
What makes it valuable.valuable.
Real-Time & Complete Data Streams
Buyers expect continuous, uninterrupted glucose readings at consistent intervals (1–15 min) with minimal gaps. Data must include timestamps, glucose values, and associated event tags (meals, exercise, medications).
Standardized Metrics & AGP Reports
Data should conform to 2019 International Consensus standards, including 10 discrete CGM metrics (time in range, time below range, glycemic variability) and Ambulatory Glucose Profile (AGP) visualizations for clinical decision-making.
Device Accuracy & MARD Performance
Sensor accuracy must be validated; Mean Absolute Relative Difference (MARD) typically ranges 7.6–8.7%. Buyers require calibration data and error margins documented for clinical and research use.
Multi-Source Integration & Accessibility
Data must integrate with external services (food trackers, insulin pump systems, EHR platforms) and be available through standardized vendor APIs or aggregator platforms with documented data governance and user consent.
Potential applications and organizations
Who's buying.buying.
Manufactures and markets CGM devices; acquires user glucose data to improve sensor technology and develop integrated automated insulin delivery systems.
Leading CGM device manufacturer and data platform operator; cleared first over-the-counter continuous glucose monitor (Stelo); collects and analyzes user data for product refinement and clinical evidence.
Major medical device company integrating CGM data with insulin pump systems for automated insulin delivery; uses datasets to validate closed-loop algorithms.
Prominent CGM device manufacturers investing in sensor innovation and clinical validation; acquire glucose datasets to support product development and market expansion.
FAQ
Common questions.questions.
What makes CGM data valuable for AI and research?
CGM data provides continuous, real-time glucose readings at intervals of 1–15 minutes, creating dense longitudinal datasets that capture glycemic variability and individual response patterns. This granular data trains diabetes management AI, meal-prediction algorithms, and exercise-response models far more effectively than traditional finger-stick testing. Event tagging (meals, medications, exercise) integrated with glucose readings enables researchers to correlate dietary and behavioral factors with glucose outcomes.
Who can legally buy and sell CGM data?
Healthcare providers, medical device manufacturers, clinical research organizations, and third-party data aggregator platforms can negotiate data-sharing agreements with CGM device vendors and users. Contracts typically govern data use rights, patient consent requirements, and compliance with healthcare privacy regulations (HIPAA, GDPR). Many vendors retain ownership but license data access to approved clinical, academic, and commercial research partners.
How accurate is CGM data?
CGM sensor accuracy is measured by Mean Absolute Relative Difference (MARD), typically ranging 7.6–8.7% depending on the device and calibration. Modern sensors have achieved significant improvements through advanced technology and increased competition among manufacturers. Data quality depends on proper sensor placement, calibration, and user compliance. Validation through clinical trials and manufacturer performance claims is standard.
What's driving rapid growth in the CGM market?
Multiple factors drive growth: rising global diabetes prevalence, FDA clearance of over-the-counter devices (e.g., Dexcom Stelo), increasing adoption among non-diabetics for wellness optimization, technological improvements in sensor accuracy and wear time, declining device costs, supportive government policies, and strategic partnerships between device manufacturers and insulin pump makers. The market is projected to grow from USD 8.98 billion (2025) to USD 17.12 billion (2030) at a 13.76% CAGR.
Sell yourcontinuous glucose monitordata.
Describe your continuous glucose monitor data and the uses you are authorized to offer. Price, legal suitability, and buyer interest require separate evaluation. No match or sale is guaranteed.
Prepare a Listing